hit counter
ASLAN Pharmaceuticals Limited (ASLN) Stock News Sentiment & Price - Sentifly
ASLN - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



ASLAN Pharmaceuticals Limited (ASLN)

Singapore
Biotechnology
NASDAQ
ASLN Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ASLN Latest news
GlobeNewsWire
Neutral
ASLAN Pharmaceuticals Announces KOL Event Series to Discuss Atopic Dermatitis Treatment Landscape and ASLAN004
2021-10-18 07:00

- Management to host the first in a series of KOL webinars beginning Monday, October 25, 2021, at 10:00am ET

GlobeNewsWire
Neutral
ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology
2021-10-14 07:00

MENLO PARK, Calif. and SINGAPORE, Oct. 14, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointments of Dr Melinda Jennifer Gooderham, MSc MD FRCPC, Dr Jacob Thyssen, MD PhD DmSci, and Associate Professor Peter Foley, BMedSci MBBS MD FACD, as members of its Scientific Advisory Board (SAB).

Pulse2
Negative
ASLN Stock: Why It Fell Over 25% Today
2021-09-27 08:20

The stock price of Aslan Pharmaceuticals Ltd (NASDAQ: ASLN) fell by over 25%. This is why it happened.

Benzinga
Negative
Why Did ASLAN Pharma Shares Plunge Despite Positive Atopic Dermatitis Trial Data?
2021-09-27 07:40

ASLAN Pharmaceuticals Ltd (NASDAQ: ASLN) has announced topline data from its Phase 1 study of ASLAN004 for moderate-to-severe atopic dermatitis (AD).  In March 2021, ASLAN announced interim data from three dose-escalation cohorts (200mg, 400mg, and 600mg).

GlobeNewsWire
Neutral
ASLAN Pharmaceuticals Announces Positive Data Conclusively Establishing Proof of Concept for ASLAN004 in Atopic Dermatitis
2021-09-27 06:00

- Topline data from multiple-ascending-dose study supports a potentially differentiated safety and efficacy profile

GlobeNewsWire
Neutral
ASLAN Pharmaceuticals to Participate in the 2021 Cantor Virtual Global Healthcare Conference
2021-09-22 07:00

MENLO PARK, Calif., and SINGAPORE, Sept. 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced Dr Carl Firth, CEO, is scheduled to give a company presentation at the 2021 Cantor Virtual Global Healthcare Conference on September 30, 2021, at 9:20am ET. The conference will be held from September 27 to September 30, 2021.

GlobeNewsWire
Neutral
ASLAN Pharmaceuticals Establishes Scientific Advisory Board Chaired by Distinguished Dermatology Expert Dr Lawrence Eichenfield
2021-09-21 07:00

MENLO PARK. Calif. and SINGAPORE, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Dr Lawrence Eichenfield, MD, FAAD, as chair of its Scientific Advisory Board, comprising experts in dermatology and allergic disease from the United States, Canada, Europe, and Asia. Dr Eric Simpson, MD, MCR, was also appointed as a board member.

Zacks Investment Research
Positive
Implied Volatility Surging for ASLAN Pharmaceuticals (ASLN) Stock Options
2021-09-13 11:11

Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.

GlobeNewsWire
Neutral
ASLAN Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-06 07:00

SINGAPORE, Aug. 06, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the second quarter ended June 30, 2021, and provided an update on recent corporate activities.

Benzinga
Neutral
ASLAN Pharma Secures Debt Funding Of $45M To Support ASLAN003 Development
2021-07-13 08:03

ASLAN Pharmaceuticals (NASDAQ: ASLN) has closed a secured loan facility provided by K2 HealthVentures (K2HV).  Under the terms of the facility, K2HV will provide ASLAN up to $45 million of secured debt financing consisting of a $20 million initial term loan funded at closing, with the remaining $25 million subject to specific terms and conditions.

Loading more news...